Wet Age-Related Macular Degeneration

The final patient has been enrolled in a phase 2b trial of Graybug Vision’s wet age-related macular degeneration treatment candidate, according to a press release.

Santen and Tracon Pharmaceuticals have discontinued development of DE-122, their wet age-related macular degeneration treatment candidate, following data analysis of a phase 2a study, the companies announced in a press release.

Novartis is conducting a comprehensive product quality review of Beovu, a treatment for wet age-related macular degeneration, after the American Society of Retina Specialists shared an update with its membership on possible side effects of the therapy.

Representatives from Novartis stood behind the safety and efficacy of Beovu, a treatment for wet age-related macular degeneration, after the American Society of Retina Specialists shared an update with its membership on possible side effects of the therapy.

The European Commission has approved Beovu for the treatment of wet age-related macular degeneration, Novartis announced in a press release.

We now have our fourth anti-VEGF drug, Beovu from Novartis. Each of the available drugs — Avastin, Lucentis, Eylea and Beovu — typically requires three monthly injections to initiate therapy. After three monthly injections are given, many patients can be converted to less frequent injections, depending on which drug is used, using a treat-and-extend approach. Patients who do not respond to one drug may respond to another. Those of us who comanage these patients with our retina colleagues need to be especially mindful of the postoperative side effects, including uveitis, both anterior and posterior, elevated IOP, secondary cataract in phakic patients and the dreaded occasional endophthalmitis.

The Bascom Palmer Angiogenesis meeting took place on Feb. 8, covering disease pathogenesis and emerging treatment options for various retinal conditions. The presentations highlighted how some of the newest imaging modalities are helping us understand the natural course of disease and new mechanisms of action being evaluated as alternatives to our current treatments. Below is just a mere highlight of many excellent presentations at the meeting.

EyePoint Pharmaceuticals and Equinox Science have signed an exclusive license agreement for the development of vorolanib, according to a press release.

Exonate announced a collaboration with Janssen Pharmaceuticals to develop new eye drops to treat retinal vascular diseases.

KOLOA, Hawaii — Despite fixed, frequent dosing being optimal for wet age-related macular degeneration management, ophthalmologists tend to favor non-fixed regimens like treat-and-extend in clinical practice, according to a presenter at Retina 2020.